---
title: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870920/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231024180819&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Erdafitinib therapy resulted in significantly longer overall
  survival than chemotherapy among patients with metastatic urothelial carcinoma and
  FGFR alterations after previous anti-PD-1 or anti-PD-L1 treatment. (Funded by Janssen
  Research and Development; THOR ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Erdafitinib therapy resulted in significantly longer overall survival than chemotherapy among patients with metastatic urothelial carcinoma and FGFR alterations after previous anti-PD-1 or anti-PD-L1 treatment. (Funded by Janssen Research and Development; THOR ClinicalTrials.gov number, ...